iberdomide

FDA Drug Profile — ZENBEXUS

iberdomide is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including ZENBEXUS. Available dosage form: capsule.

Drug details

Generic Name
iberdomide
Brand Names
ZENBEXUS
Application Number
NDA221075
Sponsor
E.R. Squibb & Sons, L.L.C.
NDC Codes
2
Dosage Forms
CAPSULE
Routes
ORAL
Active Ingredients
IBERDOMIDE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE ZENBEXUS is indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ZENBEXUS is a cereblon-modulating protein degrader indicated in combination with daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. (1) This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.